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Abstract: Background: In a randomized controlled trial (RCT) with binary outcome the estimate of
the marginal treatment effect can be biased by prognostic baseline covariates adjustment. Methods
that target the marginal odds ratio, allowing for improved precision and power, have been devel-
oped. Methods: The performance of different estimators for the treatment effect in the frequentist
(targeted maximum likelihood estimator, inverse-probability-of-treatment weighting, parametric
G-computation, and the semiparametric locally efficient estimator) and Bayesian (model averaging),
adjustment for confounding, and generalized Bayesian causal effect estimation frameworks are
assessed and compared in a simulation study under different scenarios. The use of these estimators is
illustrated on an RCT in type II diabetes. Results: Model mis-specification does not increase the bias.
The approaches that are not doubly robust have increased standard error (SE) under the scenario
of mis-specification of the treatment model. The Bayesian estimators showed a higher type II error
than frequentist estimators if noisy covariates are included in the treatment model. Conclusions:
Adjusting for prognostic baseline covariates in the analysis of RCTs can have more power than
intention-to-treat based tests. However, for some classes of model, when the regression model is
mis-specified, inflated type I error and potential bias on treatment effect estimate may arise.
Keywords: randomized controlled trial; causal inference; doubly robust estimation; propensity score
1. Introduction
Baseline covariates impact the outcome in many randomized controlled trials, and a
recent systematic review reported that 84% of the trials present adjusted analysis. Among
them, 91% pre-specified in the protocol such adjusted analysis [1]. It has been shown that
models that adjust for baseline covariates can substantially improve the statistical power of
the analysis when the covariates are moderately to strongly prognostic.
While this is justified for continuous outcomes, for binary outcomes, which require
non-linear models, covariate adjustment may change the magnitude of the treatment effect,
and thus the situation is subtler [2]. Due to the non-collapsibility of odds ratios, the non-
adjusted and adjusted analyses estimate the marginal and the conditional treatment effect,
respectively. However, the overall effect of adjusting for baseline covariates in logistic
regression is still an increase in power. This is because the marginal estimate is always
closer to the null effect than the conditional one, and the impact of the loss of precision
on the power of the conditional estimate is offset by the larger effect size, leading to a net
increase in power for the adjusted analyses [2,3].
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The large amount of baseline covariates collected in an RCT opens the possibility
to select the combination of covariates that results in the most favorable treatment effect
estimate and/or the lowest p-value [4].
This is well-recognized in the “Guideline on adjustment for baseline covariates in
clinical trials”, issued by the European Medicines Agency (EMA) in 2015, which requires
pre-specification in the protocol of the variables to be included in the primary analysis for
preventing the potential selection of the combination of covariates that may influence the
treatment effect, especially in non-linear models [5].
However, pre-specification of the variables to be adjusted for is not always feasible as
all prognostic variables may be not known in advance.
Under the frequentist approach, doubly robust and semi-parametric efficient esti-
mators allow for the separation of treatment effect estimation from baseline covariate
adjustment [6–8]. This is achieved by the inverse-probability-of-treatment weighting
(IPTW) estimator, the parametric G-computation, the semiparametric locally efficient (SLE)
estimator and the more recent targeted maximum likelihood estimator (TMLE). Under the
Bayesian framework, model averaging is an alternative to the more common approach of
model selection [9], which relies on estimation from a single model. While Bayesian model
averaging (BMA) successfully accounts for model uncertainty in making a prediction, its
advantages are less straightforward when used within the causal inference framework.
In the context of causal treatment effect estimation, BMA tends to assign large posterior
probabilities to models that may not accurately adjust for confounding. To overcome this
drawback, the Bayesian adjustment for confounding (BAC) algorithm has been proposed
as an alternative approach based on the specification of both an outcome and a treatment
model, as in the propensity score framework [10].
However, since BMA and BAC are based on models that likely contain noisy prog-
nostic covariates, they lose precision in estimating the treatment effect. To overcome this
limitation, the generalized Bayesian causal effect estimation (GBCEE) has been proposed
as a further unbiased and efficient estimator [11].
This study investigates which methods of adjusting for baseline covariate in the
analysis of RCTs with binary endpoint maximize the statistical power while retaining the
type I error rate and unbiased estimate of treatment effect. Such comparison is justified
because type I error and power are still the study operating characteristics of concern
healthcare regulators require when appraising the results of confirmatory clinical trials [12].
In the following, in Section 2.1, the motivation example is introduced. Then in
Section 2.2, the simulation study is explained, and the frequentists and Bayesian estimators
are briefly presented. Results of both simulation and the illustrative study will be reported
in Section 3 and finally discussed in Section 4.
2. Materials and Methods
2.1. Illustrative Study and Simulated Data
Our simulation study was based on the motivating example of re-analyzing the PRO-
LOGUE RCT [13]. The PROLOGUE study is among the largest trials investigating whether
DPP-4 inhibitors provide cardiovascular protective effects to patients with type 2 diabetes
by slowing carotid stiffness progression associated with conventional diabetes treatment.
The study participants were either allocated to add-on DPP-4 inhibitor (sitagliptin)
treatment or to continue therapy with conventional anti-diabetic agents. The primary end-
point was the arterial stiffness of annual changes, which resulted in being not significantly
different between the two groups. However, the study showed that the decrease in glycated
haemoglobin (HbA1c) in patients treated with sitagliptin was superior to conventional
therapy, proving a better glycemic control. As a re-analysis of the PROLOGUE study, we
then investigated a potential sitagliptin effect on the improvement of HbA1c.
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2.2. Simulation Study
The simulation study was carried out to compare the performance of several estimators
applied to obtain a marginal treatment effect estimate in the case of a binomial outcome
and was based on the same scheme adopted in Zhang et al. [14].
There was a 50% chance of being assigned to either the treatment or the control group.
The treatment assignment variable (Z) was generated as Bernoulli with P(Z = 1) = P(Z = 0)
= 0.5. The assignment Z = 1 corresponds to the treatment group. The baseline covariates
were generated as follows:
• X1, X3, X8 follow a Normal (0,1) distribution;
• X4 follows a Bernoulli (0.3) distribution;
• X6 follows a Bernoulli (0.5) distribution;
• X2 was generated as 0.2× X1 + 0.98 U1
• X5 was generated as 0.1× X1 + 0.2× X2 + 0.97 U2
• X7 was generated as 0.1× X3 + 0.99 U3
where U1, U2, U3 are Normal (0,1) variables.
Finally, Y was generated as Y = logit (P(Y = 1 |Z, X)) = α + βZ + γX, where
X = (X1, . . . , X8) is the matrix of covariates, α = 0.9, β = 1.3, γ = (0.5, 1.3, 0.5, 1.5, 0, 0, 0, 0).
The parameter β is the conditional treatment effect; α is the intercept and γ is the vector of
the coefficients of covariates X1, . . . , X8. Thus, X1, . . . , X4 variables represent prognostic
patient features for treatment effect.
To find the marginal treatment effect, one million individuals were simulated, and
30 repetitions were performed. The marginal treatment effect was then calculated as the
mean of the treatment effects as the log odds ratios using unadjusted logistic regression.
The true marginal treatment effect resulted in being equal to −0.871 ± 0.004.
For the simulation study, 5000 datasets of sample size n = 200 were generated. For
the frequentist estimators, several scenarios were defined to evaluate the effects of model
selection and are reported in Table 1.
Table 1. Scenarios under which the estimators were compared. The model for outcome generation is
Y = logit P(Y|Z, X) = 0.9 + 1.3Z + 0.5X1 + 1.3X2 + 0.5X3 + 1.5X4 .
Scenario Outcome Model Estimated Prognostic Variables in theOutcome Model Estimated
Non-Prognostic Variables in the
Outcome Model Estimated
Correct E(Y|Z, X) = α+ βZ+
γ1X1 + γ2X2 + γ3X3 + γ4X4
X1, X2, X3, X4 none
Misspecification E(Y|Z , X) =
α+ βZ + γ3X3 + γ5X5
X3 X8
All-variables
E(Y|Z, X) = α+ βZ+
γ1X1 + γ2X2 + γ3X3 + γ4X4 +
γ5X5 + γ6X6 + γ7X7 + γ8X8
X1, X2, X3, X4 X5, X6, X7, X8
Frequentist estimators were compared on all the three scenarios. Bayesian estimators were compared on all-variables scenario, only.
The model estimated under the correct scenario is the same used to generate the
outcome data when all prognostic variables are known. The model estimated under the
mis-specification scenario includes only one prognostic variable and an additional noisy
variable. Finally, the model estimated under the all-variables scenario includes all the
prognostic variables as well as non-prognostic variables and mimics the situation of using
all patient features for the treatment effect estimation in the case of uncertainty about
knowledge on prognostic variables.
2.2.1. Frequentist Estimators
The frequentist estimators employed for the estimation of the treatment effect are
briefly presented. In describing the estimators, we will refer to the treatment model as the
conditional probability (likelihood) of being treated given the covariates, i.e., P(Z|X) , and
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to the outcome model as the probability, i.e., likelihood, of the outcome given the treatment
and the prognostic covariates, i.e., P(Y|Z, X).
G-computation. To address confounding, G-computation relies on the estimation of the
outcome model, i.e., the conditional expectation of the outcome given the treatment and
the prognostic covariates. Contrary to the propensity score methods, it does not require
estimating the exposure mechanism or treatment model, i.e., the conditional probability of
being treated given the observed confounders [15].
Doubly Robust Estimation. Doubly robust (DR) estimation combines the outcome model
and treatment model. Both the models are unbiased only if they are correctly specified.
The DR estimation ensures that when combining the two models for the treatment effect
estimation, only one of them must be correctly specified to obtain an unbiased estimate.
The estimates of the parameters of interest of the outcome model and the treatment model
are used to predict patients’ responses under the treatment condition and the treatment
assignment (propensity score), respectively. Inversely weighting the expected response
under treatment condition by the propensity score allows us to represent the estimator of
the quantity of interest as an unbiased estimate plus a second term. This term reduces to 0
if either the treatment model or the outcome model are correctly specified and if, and only
if, the possibly incorrect conditional density has the same support as the true conditional
density [6].
Semi-Parametric Locally Efficient Estimator. It uses a semi-parametric model for the
outcome model, which is used to generate predicted values separately from the treatment
model. Finally, it computes the average treatment effect as the mean difference in predicted
outcome pair across individuals [16].
Targeted Maximum Likelihood Estimator. TMLE is a doubly robust, maximum-likelihood–
based estimation method that includes a secondary targeting step that optimizes the bias-
variance tradeoff for the estimation of the parameter of interest. TMLE is particularly
attractive for causal effect estimation in RCT analysis. First, it is a doubly robust method,
which yields unbiased estimates if the treatment model is correctly specified, which is the
case of RCT setup [17].
Augmented Inverse Probability Weighting. Propensity scores are estimated and used
to create inverse probability weights; all observations are weighted. Finally, it computes
the average treatment effect as the mean difference between weighted outcomes among
exposed and unexposed [18].
2.2.2. Bayesian Estimators
Bayesian Model Averaging. BMA is an extension of the Bayesian inference methods. In
addition to the usual modelling of parameter uncertainty through the prior distribution, it
models the uncertainty of the model selection process, obtaining a posterior parameter and
posterior probability model through Bayes’ theorem. In the present work, we considered
Zellner’s g distribution as a-priori distribution on coefficients for the variable selection [19]
and the Bayesian adaptive sampling algorithm for the model selection [9].
Bayesian Adjustment for Confounding. As in the propensity score framework, BAC
requires the definition of the outcome model, which is a function of the treatment and
potential confounders, and the treatment model, which is a function of the potential
confounders to treatment assignment. Then it applies a Bayesian variable selection process
in both models to select covariates and introduces a dependence parameter between the
outcome and treatment model,ω, which denotes the prior odds of including a confounder
in the outcome model, given that the same confounder is in the exposure model. In the
special case of dependence parameterω = 1, BAC reduces to BMA [10].
Generalized Bayesian Causal Effect Estimation. The generalized Bayesian causal effect
estimation (GBCEE) algorithm performs variable selection and delivers doubly robust
estimates. It employs a prior distribution that targets the selection of true confounders and
predictors of the outcome. It thus takes advantage of the Bayesian framework to account
for uncertainty in the model selection process. It is different from BMA in building the
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prior distribution. It uses a prior distribution tailored to identify the potential confounders,
which uses information from the data and thus relies on the empirical Bayes approach.
Finally, it adds a doubly robust estimation, employing the posterior distribution of the
parameters and adopting the TMLE framework to estimate the causal effect that protects
against model mis-specification [11].
3. Results
3.1. Simulation Study
For each method, we computed the bias as the difference between the average of the
estimates and the true effect. The standard error (SE) of the estimates, the Monte Carlo
standard error for the standard deviation (MC SD) and the coverage probability (CP), i.e.,
the proportion of simulation replicates in which the 95% confidence intervals included the
true effect. For the frequentist estimators, 95% confidence intervals were computed. For
the Bayesian estimator GBCEE, 95% confidence intervals were computed as well, using
50 non-parametric bootstrap replicates with the percentile method. For the BAC and BMA
approach, the 95% credible intervals were computed.
Type I error and power were also calculated. For both frequentist and Bayesian
estimators, type I error was computed simulating 5000 datasets under the null hypothesis
that the treatment is not effective. For BAC and BMA, type I error was estimated by the
proportion of the simulations incorrectly declared the treatment effective, based on the
posterior probability P(β < 0|Y, X1, . . . , X8) ≥ 0.95.
Similarly, the power was calculated as the proportion of simulations that declare the
trial successful based on the given decision criteria when the target treatment effect is
assumed to be the true value. This approach has been recommended by the FDA [20].
The performance of the frequentist estimators was assessed under three scenarios:
the ideal case of the correct model specification (correct scenario); the case of important
prognostic variable not identified in the model specification (mis-specification scenario);
finally, the case when noisy prognostic variables are introduced in the model (all-variables
scenario). In the all-variables scenario, for SLE estimator, a model selection process was
foreseen based on backward and forward stepwise techniques.
Bayesian estimators’ performance was assessed on the all-variables scenario only
since they do not require selecting a final model but allow for averaging over the space of
potential models that could have generated the data.
Results of the simulation study are reported in Table 2. The bias is similar across all
methods, while more variation is observed in the power of the estimators, ranging between
84.6% and 94.9%. For Bayesian estimators, the power is given by the posterior probability
of observing a treatment marginal effect greater than zero. A slight inflation of type I error
is observed, except for BMA, however, it is not greater than 6.5%.
3.2. Illustrative Study
To illustrate the effect of baseline adjustment on the treatment effect estimation, we
applied the introduced methods to re-analyze the PROLOGUE RCT [13].
The PROLOGUE RCT aimed to investigate whether DPP-4 inhibitors provide cardio-
vascular protective effects to patients with type 2 diabetes.
The study participants were either allocated to add-on DPP-4 inhibitor (sitagliptin)
treatment or to continue therapy with conventional anti-diabetic agents. The study showed
that the decrease in glycated haemoglobin (HbA1c) in patients treated with sitagliptin was
superior to conventional therapy, proving a better glycemic control.
We set as outcome an improvement of at least 1% in HbA1c, obtaining a dichotomised
outcome. This choice is motivated by the observation that two large-scale studies—the UK
Prospective Diabetes Study (UKPDS) and the Diabetes Control and Complications Trial
(DCCT)—demonstrated that improving HbA1c by 1% (or 11 mmol/mol) for people with
type 1 diabetes or type 2 diabetes cuts the risk of microvascular complications by 25%.
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Table 2. Results of the simulation study. In semiparametric locally efficient (SLE)/all-variables scenario, a model selection
process based on backward (SLE backward) and forward (SLE forward) stepwise techniques were foreseen.
Method Scenario BIAS SE MC SD Power Type IIError CP
Type I
Error
SLE All variables −0.010 0.246 0.015 0.947 0.053 0.941 0.061
SLE Backward All variables −0.011 0.247 0.015 0.947 0.053 0.941 0.061
SLE Forward All variables −0.010 0.246 0.015 0.947 0.053 0.941 0.061
TMLE All variables −0.011 0.248 0.015 0.947 0.053 0.939 0.065
G-Comp All variables −0.011 0.248 0.015 0.943 0.057 0.944 0.060
AIPTW All variables −0.011 0.248 0.015 0.942 0.058 0.942 0.058
DR All variables −0.013 0.298 0.010 0.943 0.057 0.940 0.059
SLE Mis-specification −0.010 0.246 0.015 0.856 0.144 0.951 0.051
TMLE Mis-specification −0.011 0.248 0.016 0.852 0.148 0.947 0.056
G-Comp Mis-specification −0.011 0.248 0.016 0.846 0.154 0.949 0.054
AIPTW Mis-specification −0.008 0.244 0.015 0.847 0.153 0.948 0.053
DR Mis-specification −0.008 0.244 0.015 0.847 0.153 0.948 0.052
SLE Correct −0.008 0.244 0.015 0.949 0.051 0.946 0.056
TMLE Correct −0.012 0.296 0.010 0.949 0.051 0.946 0.054
G-Comp Correct −0.012 0.296 0.010 0.949 0.051 0.947 0.052
AIPTW Correct −0.012 0.298 0.011 0.949 0.051 0.948 0.052
DR Correct −0.013 0.295 0.011 0.949 0.051 0.947 0.053
GBCEE All variables −0.014 0.147 0.022 0.916 0.084 0.952 0.063
BAC All variables −0.015 0.299 1 0.046 0.902 0.098 0.945 0.045
BMA All variables −0.051 0.451 1 0.090 0.922 0.078 0.942 0.02
1 The value is the standard deviation of the posterior distribution. Semi-parametric Locally Efficient (SLE) Estimator: Targeted Maximum
Likelihood Estimator (TMLE); G-Computation (G-Comp); Augmented Inverse Probability Weighting (AIPTW); Doubly Robust (DR);
Generalized Bayesian Causal Effect Estimation (GBCEE); Bayesian Adjustment for Confounding (BAC); Bayesian Model Average (BMA).
As prognostic covariates, we used age (years), gender (female, male), body mass
index (BMI, kg/cm2), systolic blood pressure (SBP, mmHg), low-density lipoprotein (LDL,
mg/dL), high-density lipoprotein (HDL, mg/dL), HbA1c (%), fasting plasma glucose
(FPG, mmol/L), dyslipidemia (LDL ≥ 130 mg/dL odds ratio (OR) HDL < 35 mg/dL
OR triglyceride ≥ 150 mg/dL OR total cholesterol (=LDL + HDL + (Triglyceride/5)) ≥
200 mg/dL).
In Figure 1, the unadjusted OR of improving HbA1c by 1% is reported along with 95%
confidence interval. Frequentist estimates are reported with 95% confidence intervals, and
finally, Bayesian estimates with 95% credible intervals are listed.




Figure 1. Odds ratio 1% change in Hba1c at 24 months. 
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is the standard measure of treatment effect reported when analyzing RCTs [23]. Although 
it is known from the literature that adjustment for prognostic covariates can increase the 
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We compared several frequentist and Bayesian estimators under different scenarios. 
The selected estimators were: SLE estimation, TMLE, G-computation, AIPTW, DR estima-
tor, GBCEE, BMA and the Bayesian adjustment for confounding algorithm. We assessed 
their performance under three scenarios: the ideal case of the correct model specification; 
the case of important prognostic variable not identified in the model specification (model 
mis-specification); finally, the case when noisy prognostic variables are introduced in the 
model (all variables selected in the adjusted analysis). Since the Bayesian estimators can 
handle the uncertainty of the model selection process assigning a posterior probability to 
each set of covariates [24], they were assessed only under the scenario of all variables in-
cluded in the adjusted analysis. 
Figure 1. Odds ratio 1% change in Hba1c at 24 months.
Int. J. Environ. Res. Public Health 2021, 18, 7758 7 of 9
4. Discussion
We have presented a study to compare different approaches to address covariate
adjustment to estimate treatment effect in RCTs.
Baseline covariates adjustment impacts the outcome in many RCTs in terms of power,
type I error and bias of the marginal effect estimation.
In fact, variable selection methods based on p-values, and large observed differences
between arms and stepwise approaches, have increased type I error rates [4]. The guide-
line on adjustment for baseline covariates in clinical trials issued by the EMA in 2015
strongly recommends pre-specifying the variables to be included in the primary analysis
in the protocol to avoid bias and potential selection of the combination of covariates that
may favour the treatment [4]. Moreover, the Consolidated Standards of Reporting Trials
(CONSORT) [21] and the International Conference on Harmonization [22] recommend to
pre-specify the potential prognostic variables to employ in adjusted analysis. However,
there is still debate on how to identify prognostic covariates correctly.
Several approaches have been proposed to estimate a marginal causal effect, which is
the standard measure of treatment effect reported when analyzing RCTs [23]. Although
it is known from the literature that adjustment for prognostic covariates can increase
the efficiency of the analysis, there is still a lack of attempts to assess comparatively the
performance of all the methods under real scenarios of analysis, including adjustment for
non-prognostic variables and model mis-specification.
We compared several frequentist and Bayesian estimators under different scenarios.
The selected estimators were: SLE estimation, TMLE, G-computation, AIPTW, DR estimator,
GBCEE, BMA and the Bayesian adjustment for confounding algorithm. We assessed their
performance under three scenarios: the ideal case of the correct model specification; the
case of important prognostic variable not identified in the model specification (model
mis-specification); finally, the case when noisy prognostic variables are introduced in the
model (all variables selected in the adjusted analysis). Since the Bayesian estimators can
handle the uncertainty of the model selection process assigning a posterior probability
to each set of covariates [24], they were assessed only under the scenario of all variables
included in the adjusted analysis.
Our results from the simulation study showed that model mis-specification does not
increase the bias. This holds also for the G-computation estimator, which is not theoretically
guaranteed to be a consistent estimator under model mis-specification.
The approaches that are not doubly robust have increased MC SD. They also showed
increased SE under the scenario of mis-specification.
Across different scenarios, frequentist estimators showed a similar precision (SE
ranges between 0.244 and 0.298). This observation is particularly interesting since the
correct specification of a parametric model with many covariates is nearly impossible [17].
Bayesian estimators behave differently, showing a high precision for GBCEE (SE = 0.147).
The uncertainty of BMA is not directly comparable with SE, since it is the standard deviation
computed on the posterior distribution. Thus it showed a larger uncertainty (0.451), which
is expected since it embeds the uncertainty of estimates in the posterior probability function.
Covariate adjustment reduced type II error but under the scenario of mis-specification
of the outcome model. The Bayesian estimators showed a higher type II error than frequen-
tist estimators under the scenario, including all prognostic variables and noisy covariates
in the model specification. On the other hand, BMA showed the largest bias, even if offset
by the smallest type I error, which is not surprising since it has been shown that the bias
can be relevant when covariates are only slightly associated with the outcome [11].
In the re-analysis of PROLOGUE RCT, we estimated the odds ratio of improving
HbA1c using the frequentist and the Bayesian estimators introduced for avoiding con-
founding. Among the Bayesian estimators, GBCEE resulted similar to other frequentist
estimators due to its doubly robust property. In contrast, BMA and BAC showed a smaller
treatment effect, compared to the unadjusted estimate.
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Adjusting for prognostic covariates leads to an increase in power, as seen by observing
that the adjusted estimate is farther from the null value of 1 than the unadjusted estimate
(odds ratio equal to 1 indicates no treatment effect). Compared to the unadjusted analysis,
we did not observe a dramatic increase of SE, thus a loss of precision, except for BMA and
BAC. However, the GBCEE Bayesian estimators showed performances comparable to other
frequentist estimators.
5. Conclusions
Adjusting for baseline covariates predictive of outcome in the analysis of RCTs can
have more power than intention-to-treat based tests. However, for some classes of model,
when the regression model is mis-specified, inflated type I error and potential bias on
treatment effect estimate may arise. Estimators that allow for separating the baseline
covariate adjustment from the treatment effect estimation can avoid potential bias for
covariates’ post hoc selection retaining the focus on objective inference on treatment effect.
Among Bayesian estimators, BMA presents the largest bias.
Our simulations were carried out in the context of a binary outcome. Similar conclu-
sions are likely to be applied to the hazard ratio since odds-ratio and hazard ratio showed
the same non-collapsibility issue.
Limitations of this study rely on the assumption of independent, identical distribution
of data, which is not necessarily the case in RCTs. Patients in RCTs often have wide vari-
ability in their response to treatment resulting in heterogeneity of treatment effect. Further
research should include realistic synthetic datasets, which capture the relationships across
clinical features among patients. Probabilistic models, classification-based imputation mod-
els, and generative adversarial neural networks are an example of data-driven approaches
of synthetic data generation methods [25].
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